Alemtuzumab and Mesalamine Controlled-Release Capsules
Determining the interaction of Alemtuzumab and Mesalamine Controlled-Release Capsules and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: alemtuzumab
Brand name: Campath, Lemtrada
Synonyms: n.a.
Generic Name: mesalamine
Brand name: Apriso, Asacol HD, Delzicol, Lialda, Pentasa, Canasa, Canasa Pac, Rowasa, SfRowasa
Synonyms: Mesalamine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Alemtuzumab-Mesalamine Delayed Release Tablets
- Alemtuzumab-Mesalamine Long-Acting Capsules (Apriso)
- Alemtuzumab-Mesalamine Long-Acting Capsules (Delzicol)
- Alemtuzumab-Mesalamine Long-Acting Capsules (Pentasa)
- Alemtuzumab-Mesalamine rectal
- Alemtuzumab-Mesalamine Rectal Enema
- Mesalamine Controlled-Release Capsules-Alemtuzumab (Campath)
- Mesalamine Controlled-Release Capsules-Alemtuzumab (Lemtrada)
- Mesalamine Controlled-Release Capsules-Alemtuzumab Intravenous
- Mesalamine Controlled-Release Capsules-Alenaze-D
- Mesalamine Controlled-Release Capsules-Alendronate
- Mesalamine Controlled-Release Capsules-Alendronate and cholecalciferol